Alex Brecher

A state-level study found that obesity-indicated GLP-1 use among Medicaid beneficiaries without diabetes was higher in states that covered the medicines for obesity. Even in states with coverage, estimated use remained low. The researchers analyzed Medicaid claims from 2016 through 2023 for beneficiaries ages 18 to 64 without diabetes. They counted claims for three GLP-1 medicines approved for obesity and used survey data to estimate each state's Medicaid population with obesity but without diabetes. Eleven states had Medicaid obesity-drug coverage in 2023. Prescription volume in the study population rose from fewer than 10,000 prescriptions per year through 2020 to about 369,000 in 2023. In that year, median estimated use was 1.4% in states with obesity coverage and 0.001% in states without it. The difference met the study's statistical threshold. Estimated use was below 5% in every state. The result remained similar when the authors accounted for uncertainty in the survey estimates and when they excluded Kansas and Mississippi, where coverage began partway through 2023. Coverage was necessary but not sufficient Formal coverage appears to be an important condition for access. States without an obesity benefit recorded almost no use in this analysis. Coverage did not produce broad access by itself, however. The low rates in covered states point to other possible barriers, including prior authorization, benefit design, medication availability, prescriber access, and the cost pressures facing state programs. The study is also useful because it excluded people with diabetes. That made the claims more specific to obesity treatment instead of mixing obesity use with GLP-1 prescriptions written for diabetes. State-level claims cannot establish causation This ecological comparison cannot prove that adopting coverage caused the higher use. States differ in many ways beyond whether their policy was classified as covered or not covered. The denominator was estimated rather than measured from individual BMI values. The researchers combined Medicaid claims with state survey estimates because BMI was unavailable in the claims. They also could not fully account for differences between the survey population and the claims population, restrictions within covered benefits, medication shortages, off-label use, or other approved indications. A filled claim does not show whether a person stayed on treatment or benefited from it. The findings describe access and use at the state level, not the right treatment choice for an individual.

A U.S. phase 2 trial found greater average weight loss with higher doses of mazdutide, an investigational medicine that activates GLP-1 and glucagon receptors. The randomized, double-blind trial enrolled 179 adults with obesity or overweight and at least one weight-related condition. None had type 2 diabetes. The 48-week study ran at 24 U.S. centers. Weekly injections were assigned as placebo, a lower-dose mazdutide schedule that increased from 3 mg to 6 mg, a 10 mg dose, or a 16 mg dose. Researchers based the primary result on relative body-weight change through the first 32 weeks. By that assessment, the adjusted mean reductions were 7.3% in the lower-dose group, 15.6% at 10 mg, and 18.1% at 16 mg. The corresponding placebo result was a 0.9% reduction. After subtracting the placebo change, the smallest treatment effect was 6.5 percentage points and the largest was 17.2. Each comparison met the trial's statistical threshold. The paper reported further average weight reduction through week 48. Gastrointestinal problems were the most common adverse events and were generally described as mild or moderate. Discontinuation because of adverse events was most frequent in the 16 mg group, where it affected 20% of participants and was mainly related to gastrointestinal disorders. Dose selection balances efficacy and discontinuation The trial provides randomized U.S. evidence across several mazdutide doses. The results show an efficacy signal and a clear reason to study dose selection carefully. The highest dose produced the largest mean loss at week 32, but it also had the highest treatment-discontinuation rate. The 3-to-6 mg group followed a different schedule from the fixed-dose groups. Participants stayed at 3 mg through week 32 and then increased to 6 mg, allowing investigators to explore the lower doses as possible maintenance options. Phase 2 results do not rank approved treatments This phase 2 study does not establish long-term effectiveness, long-term safety, or how mazdutide compares directly with approved obesity medicines. It was not designed as a head-to-head trial against semaglutide or tirzepatide. The results are group averages from 179 participants and cannot predict an individual's response. People with type 2 diabetes were not included, and the 48-week study cannot answer questions about outcomes after years of treatment. Mazdutide remains investigational in the United States. The trial was funded by Eli Lilly, and several authors reported employment and stock ownership in the company. Those disclosures do not invalidate the findings, but they belong in the evidence record when the study is interpreted.

If you have been reading about weight loss surgery for a while, you have probably run into someone who says the duodenal switch is the operation everyone should have had. You have probably also run into someone who says it wrecked their nutrition. Both of those people may be describing their own experience accurately. This is the operation family with the widest gap between what it can deliver and what it demands, and the honest version of the story needs both halves. This page explains what the biliopancreatic diversion with duodenal switch and the SADI-S actually are, what the published outcome data show and for whom, and what the follow-up commitment looks like. It is background for a conversation with a surgeon, not a way to pick an operation. How rarely it is done These are uncommon operations in the United States. In the ASMBS estimate of bariatric surgery numbers for 2023, out of roughly 270,000 procedures, biliopancreatic diversion with duodenal switch accounted for 3,775 cases, about 1.4 percent, and SADI, which ASMBS counts separately, accounted for 2,387 cases, about 0.9 percent. Sleeve gastrectomy and gastric bypass together made up the large majority. ASMBS notes that these totals are best estimates drawn from registry, claims, and inpatient data rather than an exact census. That matters practically. Experience with these operations is concentrated in relatively few centers and relatively few surgeons, so volume and follow-up infrastructure are worth asking about directly before you commit. What BPD/DS actually is The biliopancreatic diversion was first described by Scopinaro in 1979. That original operation combined a horizontal gastric resection with a rerouting that created a short common channel where food and digestive juices finally met. Patients developed bile gastritis, and the operation was modified into the duodenal switch by DeMeester in 1987. The modern version has three elements: a sleeve gastrectomy, transection of the duodenum just past the pylorus, and construction of a long alimentary limb. ASMBS describes the result for patients this way: the operation begins with a tube-shaped stomach pouch similar to a sleeve gastrectomy, and the food stream then bypasses roughly 75 percent of the small intestine, the most of any commonly performed approved procedure. That produces a significant decrease in absorption of both calories and nutrients. It is restrictive and malabsorptive at the same time, and the malabsorptive half is the dominant one. The key structural difference from a gastric bypass is where the digestive juices rejoin the food. In a duodenal switch that junction sits much further down the intestine, so the stretch of bowel where fat and the fat-soluble vitamins can actually be absorbed is short. That single design choice is the source of both the power and the cost. Because the pylorus is preserved, gastric emptying stays closer to normal than it does after the original biliopancreatic diversion. ASMBS lists dumping syndrome as a possible disadvantage of Roux-en-Y gastric bypass and does not list it for BPD/DS, though that is not a guarantee for any individual and it is not a reason to treat sugar as harmless. What SADI-S changes Single anastomosis duodeno-ileal bypass with sleeve gastrectomy, also called the one anastomosis duodenal switch, reaches a similar destination with one intestinal join instead of two. ASMBS describes it as the most recent procedure it has endorsed and notes that, while similar to BPD/DS, the SADI-S is simpler and takes less time to perform because there is only one surgical bowel connection. That is one fewer anastomosis that could leak, which is anatomy rather than a published comparative safety finding; ASMBS does not report a leak or hernia advantage for SADI-S. These are not the same operation and should not be discussed as if they were. ASMBS describes SADI-S as allowing enough absorption of vitamins and minerals to maintain healthy levels of nutrition, while listing the BPD/DS as having the highest malabsorption and the greatest possibility of vitamin and micronutrient deficiencies of the approved procedures. ASMBS also lists as a SADI-S disadvantage that it is a newer operation with only short-term outcome data. The society position statements say the same thing. The IFSO position paper on SADI-S in 2018 concluded that the procedure was likely to be a safe and efficacious treatment for adiposity and its related diseases, while noting that there was insufficient long-term data and minimal high-level evidence available. The 2020 update carries that conclusion forward and calls for enrolment in long-term multidisciplinary care, registration in national registries, and more randomized controlled trials. What the outcome data show Start with what is actually measured, in whom, and for how long, because the headline numbers move a lot depending on the comparison. SADI-S compared with gastric bypass. A 2025 systematic review and meta-analysis in Obesity Surgery pooled eight studies covering 4,259 patients, 1,625 SADI-S and 2,634 RYGB, with six studies contributing long-term outcomes at a mean follow-up of 3.93 years. SADI-S showed higher total weight loss by a mean difference of 10.03 percentage points, higher excess weight loss by 10.15 percentage points, and higher odds of diabetes remission with an odds ratio of 3.48, with a similar number of long-term complications. In the subgroup of patients with a BMI under 50, SADI-S had fewer short-term complications, fewer severe complications, and a shorter hospital stay. Important limitation: these were comparative studies rather than randomized trials, and a mean follow-up under four years is not long-term data for an operation you keep for life. SADI-S compared with the two-anastomosis duodenal switch. A 2022 meta-analysis of six studies covering 1,847 patients found the BPD/DS group had greater percentage excess BMI loss at two years than the SADI-S group, a mean difference of about 10.2 percentage points in favor of BPD/DS. In the same analysis SADI-S had shorter hospital stays and fewer long-term complications, and fewer patients with abnormal vitamin D values. The authors concluded that SADI-S is a possible alternative to BPD/DS but that further randomized studies with longer follow-up are needed. Duodenal switch compared with gastric bypass, randomized. The most direct evidence is a small randomized trial. Sixty patients with a BMI of 50 to 60 were randomized to laparoscopic RYGB or laparoscopic DS at two academic centers in Sweden and Norway, and 48 of them, 80 percent, were assessed after a median of 12 years. Mean BMI reduction was 11.0 points after RYGB and 20.3 points after DS. Total weight loss was 20.0 percent after RYGB and 33.9 percent after DS. Most serum lipid measures improved more in the DS group. That is a genuinely large weight-loss difference, and it is the strongest argument anyone makes for this operation. Note the scope before you carry those numbers anywhere. Sixty patients randomized, 48 followed, one BMI band, two centers. It is the best randomized evidence available for this comparison and it is still a small trial. The cost, stated plainly The same randomized trial reported the other side of the ledger. Total adverse events were higher after duodenal switch, 135 against 97 for gastric bypass. More patients developed vitamin deficiencies, 21 against 11, including 25-hydroxyvitamin D deficiency in 19 against 9. Bone mass fell in both groups between 5 and 10 years and was lower after duodenal switch at 10 years. Four of 29 duodenal switch patients, 14 percent, developed severe protein-caloric malnutrition. Three of them, 10 percent, underwent revisional surgery. The trial authors concluded that BMI reduction was greater after DS, but that RYGB had a better risk profile over 10 years, and that biliopancreatic diversion with duodenal switch may not be a better surgical strategy than RYGB for patients with a BMI of 50 to 60. That is a randomized trial declining to endorse the more powerful operation in precisely the population where it is most often recommended. It deserves weight in your decision even though the trial is small. A separate 2025 meta-analysis of twelve studies covering 2,678 patients with a BMI of 50 or above, followed for between one and fifteen years, found the same shape of result. Patients undergoing DS had greater BMI loss and greater total weight loss than RYGB, while rates of complications, reoperation, mortality, and comorbidity remission were not significantly different. Malnutrition occurred in 8.3 percent of the DS group against 1.2 percent after RYGB, 5.4 percent of DS patients needed revisional surgery for malnutrition against none after RYGB, and 24.6 percent of DS patients developed gallbladder disease requiring cholecystectomy against 4.5 percent after RYGB. Leak rates are not the differentiator many people assume. The reported incidence of gastric or duodenal leak after biliopancreatic diversion with duodenal switch is 1.14 percent, compared with 1.12 percent for Roux-en-Y gastric bypass, though the leak site is more often at the duodenal anastomosis after a switch. The trade is not mainly about early surgical risk. It is about nutrition over decades. The monitoring burden Biliopancreatic diversion with duodenal switch is described in the clinical literature as the one bariatric procedure associated with the greatest perioperative malnutrition and metabolic complications. Every patient begins supplementation after surgery, and close follow-up with laboratory studies is essential. Common problems include iron deficiency anemia, protein-calorie malnutrition, hypocalcemia, and deficiencies of the fat-soluble vitamins as well as thiamine, B12, and folate. The 2019 perioperative nutrition guideline puts numbers to the surveillance rhythm for one example: iron status should be monitored in all patients within the first three months after a bariatric procedure, then every three to six months until 12 months, and annually thereafter. It also sets the highest calcium targets and, for vitamins A and K, the highest maintenance amounts for BPD/DS of any procedure, recommends aggressive case finding for vitamin A in the first postoperative year after bypass or BPD/DS, and recommends at least annual screening for copper and zinc after BPD/DS even without symptoms. In practice, duodenal switch patients are usually monitored at least this closely, for life. Say the quiet part out loud before you decide. If you cannot picture yourself getting blood drawn on a schedule for decades, taking multiple supplements every single day, and calling your team when a result looks off, this is not the right operation for you. That is not a judgment about you. It is arithmetic about the operation. See why supplements are required for life after bariatric surgery and nutrient deficiencies and the labs that catch them for what that actually involves. Who these operations are for Eligibility for metabolic and bariatric surgery generally is set by the 2022 ASMBS and IFSO guidelines, which recommend surgery for people with a BMI of 35 or above regardless of the presence, absence, or severity of comorbidities, and for people with type 2 diabetes and a BMI of 30 or above, with different thresholds for Asian populations. Our page on current eligibility criteria and on whether you are a candidate covers that in full. Nothing on this page changes those criteria. Within that, the duodenal switch is typically discussed for people at the higher end of the BMI range, particularly a BMI of 50 or above, for people whose type 2 diabetes has not responded adequately to other approaches, or as a second stage after a sleeve that has not delivered the intended result. ASMBS considers BPD/DS to be the most effective approved metabolic operation for the treatment of type 2 diabetes, and a StatPearls clinical reference chapter states that it achieves the greatest mean excess weight loss and the highest rates of long-term diabetes remission among all bariatric procedures, without attaching a population or a follow-up window to that claim. Hold that alongside the randomized evidence above, which found greater weight loss but a worse overall risk profile at 10 years in the BMI 50 to 60 group. Both statements are on the record, and reconciling them for your situation is the surgeon's job, not a web page's. SADI-S is increasingly chosen instead of the two-anastomosis version because it is technically simpler and appears to carry a favorable short-term safety profile, and it is a common option for someone who already has a sleeve and is seeking further weight loss. Its very long-term data are still accumulating, which is exactly what both IFSO position statements say. If a surgeon offers you either operation, ask how many they perform a year, what their follow-up protocol looks like at year 5 and year 10, and what specifically happens if you develop malnutrition. A surgeon who welcomes those questions is the one you want. The honest summary These are high-commitment operations. In the available comparisons they deliver more weight loss than gastric bypass and strong metabolic results, and they extract a price in nutritional vigilance that does not end. Anyone who presents them as simply the strongest option without that second half of the sentence is not giving you the full picture. Anyone who presents them as reckless is not either. When to Consider Duodenal Switch as a Revision Procedure A duodenal switch is sometimes performed as a secondary or revisional procedure after a gastric band or a sleeve gastrectomy has not achieved the intended weight loss. ASMBS lists a sleeve gastrectomy as a possible bridge to a gastric bypass or SADI-S procedure, and describes SADI-S as an option for a patient who already had a sleeve gastrectomy and is seeking further weight loss. Points worth raising if a revision is on the table: These are technically demanding operations, and ASMBS lists BPD/DS as more complex surgery requiring more operative time than the alternatives. You will take vitamin and mineral supplements daily for the rest of your life, and the amounts are the highest of any approved procedure after BPD/DS. Both operations affect intestinal hormones in a way that reduces hunger and increases fullness; ASMBS says BPD/DS does this even more than gastric bypass and sleeve gastrectomy. ASMBS lists looser and more frequent bowel movements, and worsening or new reflux, as disadvantages of both BPD/DS and SADI-S. Diet after these operations is about getting enough nutrition, not only about eating less, and that is a different discipline than most people expect. Revision decisions depend on your original anatomy, why the first operation did not deliver, and what your labs and imaging show. This is a conversation with a surgeon who can see all three. Questions worth bringing to your surgeon How many duodenal switch or SADI-S procedures do you perform each year? Which of the two are you recommending for me, and why that one? What does your follow-up and lab schedule look like at year 1, year 5, and year 10? What happens, specifically, if I develop protein-calorie malnutrition? What are my alternatives, and what would you expect from a sleeve or a bypass in my case? What does the supplement regimen actually cost per month, and what happens if I cannot keep up with it? Related reading The Bariatric Procedures Done Today, Compared Gastric Sleeve: A Complete Guide Gastric Bypass: A Complete Guide Are You a Candidate? Current Eligibility Criteria Types of Bariatric Procedures Why Supplements Are Required for Life After Bariatric Surgery References American Society for Metabolic and Bariatric Surgery. Estimate of Bariatric Surgery Numbers, 2011-2023. American Society for Metabolic and Bariatric Surgery, Public Education Committee. Bariatric Surgery Procedures. Updated May 2021. Salte OBK, Olbers T, Risstad H, et al. Ten-Year Outcomes Following Roux-en-Y Gastric Bypass vs Duodenal Switch for High Body Mass Index: A Randomized Clinical Trial. JAMA Network Open. 2024;7(6):e2414340. PMID 38829616. Sabatella L, Aliseda Jover D, M Ortega P, et al. Comparison Between Single Anastomosis Duodeno-Ileal Bypass with Sleeve Gastrectomy (SADI-S) and Roux-En-Y Gastric Bypass (RYGB) in Terms of Weight Loss, Associated Medical Problems Remission, and Complications: A Systematic Review with Meta-Analysis. Obesity Surgery. 2025;35(9):3577-3590. PMID 40691384. Esparham A, Roohi S, Mehri A, et al. Roux-en-Y gastric bypass versus duodenal switch in patients with body mass index ≥50 kg/m2: a systematic review and meta-analysis. Surgery for Obesity and Related Diseases. 2025;21(2):184-193. PMID 39395846. Nakanishi H, Matar RH, Vahibe A, et al. Single Versus Double Anastomosis Duodenal Switch in the Management of Obesity: A Meta-analysis and Systematic Review. Surgical Laparoscopy, Endoscopy & Percutaneous Techniques. 2022;32(5):595-605. PMID 36130714. Brown WA, de Leon Ballesteros GP, Ooi G, et al. Single Anastomosis Duodenal-Ileal Bypass with Sleeve Gastrectomy/One Anastomosis Duodenal Switch (SADI-S/OADS) IFSO Position Statement, Update 2020. Obesity Surgery. 2021;31(1):3-25. PMID 33409979. Brown WA, Ooi G, Higa K, Himpens J, Torres A. Single Anastomosis Duodenal-Ileal Bypass with Sleeve Gastrectomy/One Anastomosis Duodenal Switch (SADI-S/OADS) IFSO Position Statement. Obesity Surgery. 2018;28(5):1207-1216. PMID 29572769. Eisenberg D, Shikora SA, Aarts E, et al. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery. Surgery for Obesity and Related Diseases. 2022. See also the ASMBS/IFSO Guidelines 2022 fact sheet. Mechanick JI, Apovian C, Brethauer S, et al. Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures, 2019 Update. Endocrine Practice. 2019;25(12). Recommendations R57, R59, R64, R65; Tables 9, 11, and 12. Conner JN, Lin S, Collier SA. Biliopancreatic Diversion With Duodenal Switch. In: StatPearls. Treasure Island (FL): StatPearls Publishing. Last updated February 15, 2026. NCBI Bookshelf NBK563193. Questions about Duodenal Switch and SADI-SWhat does this page cover?This page is an educational overview of Duodenal Switch and SADI-S. It is designed to help you prepare questions for your own bariatric care team. What should I do with this information?Use it as a starting point for a conversation with the clinician or dietitian who knows your history, procedure, and care plan. About the authorAlex Brecher founded BariatricPal, an online community for people considering or living with bariatric surgery.

The STEP 12 trial found greater average weight loss with once-weekly semaglutide 2.4 mg than with placebo among adults enrolled in mainland China and Taiwan. Both groups also received a lifestyle intervention during the 44-week treatment period. The randomized, double-blind phase 3b trial enrolled 242 adults at 19 sites. Eligibility began at a BMI of 24 for people who also had a weight-related condition. Adults in the 28 to under 30 BMI range could enroll whether or not they had type 2 diabetes. The study assigned 161 people to semaglutide and 81 to placebo. Forty-seven participants, or 19.4%, had type 2 diabetes. At week 44, average body weight had fallen 12.1% in the semaglutide group and 2.2% in the placebo group. The estimated difference was 9.9 percentage points. At least 5% weight loss was recorded for 80.5% of participants assigned semaglutide and 24.4% assigned placebo. Both comparisons met the trial's statistical threshold. Adverse events were reported by 87.6% of semaglutide participants and 75.3% of placebo participants. Problems involving the digestive system appeared most often. Safety results were analyzed descriptively, which means the trial did not test whether the difference in overall adverse-event rates was statistically significant. Regional trial evidence matters This study supplies randomized evidence from adults enrolled under BMI thresholds used in mainland China and Taiwan. Under the study conditions, adding semaglutide to the lifestyle program produced greater average weight loss than adding placebo. The study also shows why regional trial evidence matters. Entry thresholds, body composition, health profiles, clinical practice, and treatment access are not identical across populations. A trial designed for the population it enrolls can answer questions that a broad global result may not resolve. The placebo trial cannot rank active treatments No active obesity medicine served as the comparator, so the results cannot rank semaglutide against another treatment. The study also does not establish what happens after several years of therapy or after treatment is stopped. Follow-up lasted 44 weeks, and the 242-person sample was too small to characterize uncommon adverse effects. The 12.1% result is a group average, not a promised individual outcome. Missing week-44 values were handled with washout multiple imputation, so the estimate depends in part on assumptions about those missing outcomes. The PubMed abstract does not report separate weight or safety results for the subgroup with type 2 diabetes. Novo Nordisk funded the trial. Several authors reported employment, stock ownership, consulting work, or other industry relationships. Those disclosures do not erase the randomized result, but they are part of the evidence record.

Losing weight quickly is the point of the operation. It is also, inconveniently, the strongest known trigger for gallstone formation. This is one of the few complications where the thing causing the problem is the thing working correctly, which makes it worth understanding rather than worrying about. Why rapid weight loss causes stonesBile is a solution of cholesterol, bile salts and phospholipids, held in balance. Rapid weight loss disturbs that balance in more than one way at once. Fat tissue breaking down releases a large amount of cholesterol into circulation, and the liver excretes it into bile. Bile becomes supersaturated with cholesterol, meaning it holds more than it can keep dissolved. At the same time, eating far less fat means far less stimulation of the gallbladder, so it contracts less often and empties less completely. Bile sits in the gallbladder longer. Supersaturated bile plus stasis is the standard recipe for cholesterol stones. The clinical literature describes this as rapid weight loss increasing the lithogenicity of bile. How often it happensThe reported range is wide, and it depends heavily on whether the study looked for stones with ultrasound in everyone or only counted people who developed symptoms. After Roux-en-Y gastric bypass, reported incidence of gallstones ranges from 7 percent to 53 percent, with most figures clustering around 30 percent.A study of patients after sleeve gastrectomy, using ultrasound over a mean follow-up of about 20.6 months, found gallstones in 36.9 percent. Of those with stones, 31.8 percent went on to have symptoms requiring laparoscopic cholecystectomy. The mean interval from surgery to stone detection was around 210 days.A broad clinical reference puts the rate at 10 percent to 25 percent in the context of rapid weight loss generally.Two things are worth pulling out of that. First, most gallstones after bariatric surgery are found because someone looked, not because they caused trouble. Second, only a minority of people who form stones ever become symptomatic. A systematic review of cholecystectomy in bariatric patients found the incidence of biliary complications to be about 5.54 cases per 1,000 patient-years, which is a low number. The riskiest window is roughly the first 6 to 18 months, when weight is coming off fastest. What symptomatic gallstones feel likeBiliary colic. Steady, severe pain in the upper right abdomen or just below the breastbone, often radiating to the back or the right shoulder blade. It builds over minutes, plateaus for anywhere from 30 minutes to several hours, then fades. It is classically triggered by a fatty meal and it often wakes people at night.Nausea and vomiting with the pain.Milder presentations, including epigastric discomfort or nausea that is easy to mistake for ordinary post-operative food intolerance.Escalations that need urgent attention: Cholecystitis, where the gallbladder becomes inflamed and infected. Pain lasting more than a few hours, fever, and marked tenderness.Choledocholithiasis and cholangitis, where a stone lodges in the bile duct. Yellowing of the skin or eyes, dark urine, pale stools, fever with rigors.Gallstone pancreatitis. Severe pain boring through to the back, persistent vomiting.One thing worth knowing in advance if you have had a gastric bypass: because the duodenum is bypassed, standard ERCP to retrieve a stone from the bile duct is difficult or impossible. Surgeons operating on bypass anatomy are advised to image the biliary tree during the operation for exactly this reason. It does not change what you do, but it explains why your team may approach a bile duct stone differently than they would in someone with normal anatomy. UrsodiolUrsodeoxycholic acid, sold as ursodiol, reduces cholesterol saturation in bile. It is commonly prescribed for about six months after surgery, and NIDDK notes that providers sometimes prescribe preventive medication for roughly that period. Typical dosing described in the clinical literature is 300 mg twice daily after gastric bypass or duodenal switch, and 500 mg daily after sleeve gastrectomy. Now the evidence, which is more interesting than the usual summary suggests. At preventing stones from forming, ursodiol clearly works. One randomized trial found gallstones in 43 percent of the placebo group versus 8 percent of the group taking 300 mg twice daily at six months after surgery. A 2023 meta-analysis of 12 randomized controlled trials conducted between 1993 and 2022, covering 2,767 patients, found a substantially lower overall incidence of gallstones with ursodiol, with a risk ratio of 0.13, and significant reductions at three months, six months and one year. At preventing symptomatic gallstone disease, the picture is less clean. The UPGRADE trial, a multicenter double-blind randomized placebo-controlled trial of 967 patients, gave 900 mg of ursodeoxycholic acid daily for six months after primary gastric bypass or sleeve gastrectomy. It did not significantly reduce symptomatic gallstone disease over two years in the population as a whole. A subgroup of bypass patients who had no gallstones before surgery did show a reduced risk, with an odds ratio of 0.37, and the authors suggested prophylaxis may be considered for that group specifically. The reasonable reading: ursodiol reduces the number of stones that form, and it probably reduces symptomatic disease in bypass patients who started with a clean gallbladder, but the effect on the outcome patients actually care about is smaller and less certain than the stone-formation numbers suggest. It is also a twice-daily pill for six months at a time when you are already swallowing a great deal, and adherence in the real world is imperfect. Whether you take it is your surgeon's call, and practices differ legitimately between programs. If you were prescribed it, take it for the full course. If you were not, that is a defensible position and not an oversight. Why routine gallbladder removal is no longer standardFor a period, some surgeons removed the gallbladder during the bariatric operation regardless of whether it contained stones, on the reasoning that they were already in there and it would save a second operation later. That practice has been abandoned, and the reasoning is straightforward arithmetic. Most patients never develop symptomatic gallstones, so most prophylactic cholecystectomies remove a healthy organ that would never have caused trouble. Adding the cholecystectomy lengthens the operation and adds its own complication risk, including bile duct injury. And the rate of biliary complications after bariatric surgery, at roughly 5.54 cases per 1,000 patient-years, is not high enough to justify operating on everyone. A systematic review and meta-analysis of cholecystectomy in bariatric patients concluded that prophylactic cholecystectomy may be avoided in favor of a selective approach: remove the gallbladder when it is clinically indicated, and monitor everyone else for symptoms. Current surgical society guidance addresses how to manage cholecystectomy in patients who already have bypass anatomy rather than recommending routine removal at the index operation. The one nuance is that if you already have known symptomatic gallstones going into your bariatric operation, doing both at once is often reasonable, and the same meta-analysis found lower complication and reoperation risk when cholecystectomy was done concomitantly rather than as a separate later procedure. That is a different situation from removing a healthy gallbladder. If you need your gallbladder out laterIt is a common outcome and not a sign that anything went wrong. Laparoscopic cholecystectomy after bariatric surgery is a routine operation, generally done as an outpatient or with a single overnight stay. You do not need a gallbladder. Some people have looser stools for a few weeks or months afterward, which usually settles. What matters is not sitting on the symptoms. Biliary colic that has become frequent, or any episode with fever or jaundice, is worth a call rather than a wait.

Deciding to pay for this yourself is a serious financial decision, and the industry that has grown up around it is not always on your side. Some of what follows is about how to pay. Most of it is about how not to get hurt while paying. Cash-pay package pricing Most bariatric programs offer a discounted bundled price to people paying cash. North Mississippi Health Services, for example, lists a $12,650 cash price for a vertical sleeve gastrectomy. UNC Rex states that self-pay options start at $8,999 depending on the operation. The discount is real, because the hospital avoids the administrative cost of a payer and gets paid up front. What varies wildly is what the bundle contains. North Mississippi's package includes the operating room, surgeon and anesthesia fees, up to two nights of hospitalization with nursing, labs, imaging, medications and a dietary consult, follow-up exams at two weeks, six weeks and three months, dietitian visits at two and six weeks, and eight weeks of wellness center membership. WakeMed describes its package as covering the day of surgery, facility fees, surgeon fee, anesthesia, an overnight stay, and five years of follow-up care. Get the inclusion list in writing and check it against this list of things that are often outside the bundle: Pre-operative labs, endoscopy or upper GI study, cardiac and pulmonary clearance, sleep study The psychological evaluation Pre-operative nutrition visits and the pre-op liquid diet products Follow-up beyond the stated window Complication care, readmission and reoperation The single biggest risk: a package that excludes complications This deserves its own section because it is the failure mode that turns a $13,000 decision into a $60,000 one. Most bariatric surgery goes fine. But in a Medicare study of 64,537 bariatric patients operated on between 2011 and 2016, 12.5 percent were readmitted within 90 days and 22.1 percent had an emergency department visit. If you are paying cash and you are readmitted for a leak, a bleed, an obstruction or a severe dehydration episode, the cash package almost certainly does not cover it, and you are now a self-pay inpatient with no negotiated rate. Before you sign anything, ask these questions and get the answers in writing: If I have a complication within 30 days, 90 days, or a year, what is covered and what is not? Does the package cover a reoperation for a complication of this surgery? Does it cover readmission to this hospital? What about a different hospital, if I am traveling? Is there a complication insurance product offered, what does it cost, what does it cover, and what does it exclude? If a program will not answer this clearly, that is your answer about the program. Your right to a written estimate, and to a discount you may already qualify for If you are uninsured or choosing not to use insurance, federal law entitles you to a good faith estimate of the cost before you receive care. If the final bill lands at least $400 above the estimate, you can use the patient-provider dispute resolution process. Separately, if the hospital is a nonprofit that is tax-exempt under section 501(c)(3), it operates under section 501(r) of the tax code. That requires it to have a written financial assistance policy, to limit what it charges patients eligible for that assistance to no more than amounts generally billed to insured patients, and to follow reasonable billing and collection practices. Ask for the financial assistance policy by name and ask whether you qualify. People routinely take out loans without ever asking this question. Medical credit cards and the deferred interest trap You will be offered one of these in the office. Understand exactly what you are being offered. A deferred interest promotion says something like no interest for 24 months. What it means is that interest is accruing the entire time at the card's regular rate, and it is being held back. If you pay the full balance off within the promotional window, the accrued interest is waived. If you are even slightly short on the final day, the entire accrued interest for the whole period is added to your balance at once. The Consumer Financial Protection Bureau reported interest rates well above traditional consumer credit cards, 26.99 percent for medical credit cards and 16 percent for medical installment loans, and that between 2018 and 2020 consumers paid roughly $1 billion in deferred interest charges on about $23 billion of medical financing across more than 17 million transactions. The CFPB also found that finance companies train providers and supply promotional materials to encourage enrollment, that providers often cannot explain deferred interest terms, and that patients frequently do not learn about hospital financial assistance or zero-interest options first. If you use one anyway, do three things. Divide the total by the number of promotional months and pay that amount every month, not the minimum, because the minimum payment is often deliberately too small to clear the balance in time. Set a calendar reminder two months before the promotion ends. Confirm the payoff amount by phone, not from the statement. Personal loans A fixed-rate personal loan from a bank or credit union is usually the less dangerous option, because the rate does not change and there is no cliff at the end. Compare on the annual percentage rate and the total amount repaid, not the monthly payment. Check for prepayment penalties. Get a quote from your own bank or credit union as well as from the financing partner the surgical office recommends, and remember that the office has a relationship with that partner. HSA and FSA Both let you pay with pre-tax dollars, which is effectively a discount equal to your marginal tax rate. A health savings account requires you to be enrolled in a qualifying high deductible health plan. For 2026, the contribution limits are $4,400 for self-only coverage and $8,750 for family coverage. The qualifying plan must have a minimum annual deductible of $1,700 self-only or $3,400 family, with maximum out-of-pocket amounts of $8,500 and $17,000. HSA funds roll over indefinitely and the account is yours if you change jobs, which is why it is worth understanding well before surgery rather than after. A health flexible spending arrangement is available with most employer plans and has no high deductible requirement. For 2026 the salary reduction limit is $3,400, with a maximum carryover of $680 if your plan permits carryover. The whole annual election is available to you on day one of the plan year, which is genuinely useful if your surgery is in January. The catch is the use-it-or-lose-it structure beyond the carryover. On what qualifies: IRS Publication 502 states you can include amounts paid to lose weight if it is treatment for a specific disease diagnosed by a physician, such as obesity. It also states you cannot include the cost of diet food or beverages, because they substitute for what you would normally eat. Nutritional supplements and vitamins are excluded unless recommended by a medical practitioner as treatment for a specific diagnosed condition, and health club dues are not deductible. Confirm the specifics with a tax professional, because your situation is yours. Employer programs and centers of excellence networks Two things are worth asking about even if you have concluded you are paying cash. First, some employers offer bariatric surgery through a designated network arrangement rather than as a standard medical benefit, often paired with travel support. North Mississippi Health Services, for example, notes that its bariatric center is a Cigna Center of Excellence and is recognized in the Optum bariatric centers of excellence network, which extends coverage through certain employer and government employee plans. If your employer uses one of those networks, the operation may be covered at a designated center even when it looks excluded at your local hospital. Ask HR specifically about centers of excellence. Second, if your employer self-funds its plan, the exclusion is your employer's decision and your employer can change it. That is a slower path than cash, but it is worth starting in parallel rather than instead. Shopping the price without shopping away the quality Comparing quotes is worth doing, and hospitals have to publish standard charges including discounted cash prices, so the numbers are more findable than they used to be. Ask every center for the same three things in writing: the total price, the itemized inclusion list, and the complication policy. Then compare those, not the headline number. Do not choose on price alone. A cheap package with a three-month follow-up window and no complication coverage is not cheaper than an expensive one with five years of follow-up and a defined readmission policy. It is a different product. What should actually disqualify a program is not its price. It is an unwillingness to put its inclusions, its exclusions and its complication policy on paper before you pay. Take the time to do this properly. You are about to spend a large amount of money on something that will change how you live, and an afternoon spent getting written answers is the cheapest insurance available to you.

If you have been quietly taking antacids for years and have never mentioned it to your surgeon, this article is for you. Reflux is the single most under discussed factor in choosing between a sleeve and a bypass, and it is now the leading reason sleeve patients end up having a second operation. It is worth ten minutes of your attention before you sign anything. What GERD is Gastroesophageal reflux happens when stomach contents come back up into your esophagus. Everyone has it occasionally. Gastroesophageal reflux disease, GERD, is the more severe and long lasting version where reflux causes repeated bothersome symptoms or leads to complications. NIDDK estimates that about 20 percent of people in the United States have GERD. The typical symptoms are heartburn and regurgitation, but not everyone gets those. Other presentations include chest pain, nausea, pain or difficulty swallowing, chronic cough and hoarseness. Untreated over time, GERD can cause esophagitis, which is inflammation that can ulcerate and bleed, esophageal stricture, which is narrowing that makes swallowing difficult, and Barrett's esophagus, in which the lining of the esophagus is replaced by tissue resembling intestinal lining. A small number of people with Barrett's develop esophageal adenocarcinoma. Complications outside the esophagus include asthma, chronic cough, laryngitis and erosion of tooth enamel. Two of the risk factors NIDDK lists are directly relevant here: having obesity, and having a hiatal hernia, which is when the opening in your diaphragm allows the top of the stomach to slide up into the chest. How reflux gets assessed before surgery Outside of surgery, GERD is usually diagnosed from symptoms and history alone, with testing reserved for people whose symptoms suggest a complication or who do not improve on treatment. Before bariatric surgery the threshold is much lower, because what is found changes which operation you should have. The IFSO position statement on upper gastrointestinal endoscopy before and after metabolic bariatric surgery says endoscopy should be strongly considered before surgery, while stopping short of calling it mandatory. The reasoning is that symptoms predict pathology poorly. In the pooled data, 61 percent of patients had some abnormal finding on preoperative endoscopy. The common findings were gastropathy in 33 percent, hiatal hernia in 22 percent and esophagitis in 16 percent. Serious findings such as cancer or varices occurred in under 1 percent, and findings that entirely contraindicate surgery were similarly rare. The number that matters most to you is this one: roughly 23 percent of patients had findings that led to a change in the type of procedure planned, and about 35 percent needed treatment for something that was found. Nearly a quarter of people went in expecting one operation and had the plan revised. That is the whole argument for getting scoped. Other tests your team may use include esophageal pH monitoring, which NIDDK describes as the most accurate way to detect stomach acid in the esophagus, and manometry to assess how well the esophagus moves. Whether you need these is a clinical decision for your surgeon and gastroenterologist. Why the sleeve can cause or worsen reflux The sleeve removes the fundus, narrows the stomach into a high pressure tube, and can disturb the angle where the esophagus meets the stomach. If a hiatal hernia is present and not addressed, the anatomy that normally resists reflux is further compromised. The result is that a meaningful proportion of sleeve patients develop new reflux or find existing reflux gets worse. Here the evidence is genuinely contested, and you should be given a range rather than a number. A meta-analysis of nine studies found the odds of GERD were 3.61 times higher after sleeve gastrectomy, and pooled new onset GERD at 50.8 percent. Pooled erosive esophagitis by Los Angeles grade was 23.1 percent class A, 14.6 percent class B, 4.3 percent class C and 3.3 percent class D. Pooled Barrett's esophagus was 7.3 percent. The authors concluded that endoscopic surveillance is warranted after sleeve even in patients with no reflux symptoms. A review of studies with 10 years or more of follow up, covering 1,020 patients, put new onset GERD at 32.3 percent with a range of 21.4 to 58.4 percent, and found Barrett's in 0.5 percent. The IFSO endoscopy statement cites de novo Barrett's esophagus at approximately 3.53 percent after sleeve. In the SLEEVEPASS randomized trial at 10 years, esophagitis was found in 31 percent of sleeve patients against 7 percent of bypass patients, and 64 percent of sleeve patients were taking proton pump inhibitors against 36 percent after bypass. Barrett's esophagus was found in 4 percent of each group, with no statistically significant difference between them. Why the enormous spread? Because studies measure different things. Symptom questionnaires and endoscopic findings disagree with each other in both directions, some people have esophagitis without symptoms and some have symptoms without visible damage. Follow up lengths differ. Whether hiatal hernias were sought and repaired differs. And Barrett's estimates in particular swing from under 1 percent to over 7 percent depending on who was scoped and when. What is consistent across every one of these sources is the direction. Reflux is more common after sleeve than after bypass, and it does not reliably settle down with time. The other side is real too. Obesity itself causes reflux, and losing a large amount of weight relieves it for some people. Some sleeve patients see their pre-existing reflux improve. You should not assume you will be in that group, and you should not assume you will not be. Why bypass generally improves reflux After a Roux-en-Y gastric bypass, acid is produced in the remnant stomach, which is no longer connected to your esophagus. The small pouch holds very little and has no significant acid production of its own. Anatomically, the path for acid to reach the esophagus is largely gone. The behavioral changes help as well. You eat smaller meals, you eat more slowly, and the post operative diet limits fatty foods, alcohol and caffeine, all of which aggravate reflux. This is why gastric bypass is often recommended outright when a patient has significant GERD going in, and it is why the SLEEVEPASS esophagitis and PPI figures separate so sharply. Hiatal hernia repair at the time of surgery If you have a hiatal hernia, your surgeon should identify it and repair it during your bariatric operation, usually by approximating the crura of the diaphragm behind the esophagus. This is standard practice and it is worth confirming it is in your plan. Be clear eyed about what it buys you. A meta-analysis of sleeve gastrectomy with concurrent hiatal hernia repair found significant reduction in GERD symptoms with an odds ratio of 0.20 and improvement in esophagitis with an odds ratio of 0.12. GERD remission occurred in 68 percent. Compared with sleeve alone, the combined procedure was clearly better for resolving existing GERD, with an odds ratio of 2.97. However, de novo GERD still occurred in about 12 percent, and there was no significant difference in de novo GERD between sleeve with hernia repair and sleeve alone. Hiatal hernia recurrence was 11 percent. So repairing the hernia helps existing reflux considerably. It does not appear to prevent new reflux from developing. That distinction is often blurred in consultations and it should not be. Barrett's esophagus Barrett's is a change in the esophageal lining caused by chronic acid exposure, and it is the main reason reflux is treated as more than a comfort issue. If you already have Barrett's, the IFSO position is that bypass procedures may be preferred over reflux promoting procedures like sleeve gastrectomy, arrived at through shared decision making, and that you should continue standard gastroenterology surveillance rather than a bariatric specific schedule. Post sleeve surveillance guidance has actually loosened. Rather than routine endoscopy every two to three years for everyone, the current suggestion is endoscopy for patients with alarm symptoms such as difficulty swallowing, unexplained weight loss or bleeding, or for refractory reflux. Your gastroenterologist decides what applies to you. Conversion from sleeve to bypass This is now one of the most common operations in bariatric surgery. In the MBSAQIP database for 2020 and 2021, 13,432 patients underwent conversion from sleeve to bypass compared with 84,543 primary bypasses. GERD was the indication in 55.3 percent of those conversions, ahead of weight regain at 24.4 percent and inadequate weight loss at 12.7 percent. A separate MBSAQIP analysis of 2020 data found sleeve to bypass was the single most common conversion performed, at 40.3 percent of all conversions, with GERD driving 54.2 percent of them. Conversion is safe but not free. Compared with primary bypass, conversion had longer operative times, 145 minutes against 125, and a higher rate of serious complications, 7.2 percent against 5.0 percent. Anastomotic leak was 0.5 percent against 0.4 percent, bleeding 2.0 percent against 1.6 percent, and reoperation 3.0 percent against 1.9 percent. Mortality was 0.1 percent in both groups and was not different. Conversion was an independent predictor of serious complications but not of death. For most people with intractable reflux after a sleeve, those odds are acceptable. It is still a second operation, and knowing that going in is better than discovering it in year four. What to do with all of this Tell your surgeon about every antacid, every episode of night time coughing, every time food has come back up. Underreporting reflux to get the operation you already picked is a bad trade. Ask whether you are getting a preoperative endoscopy and what it showed. Ask specifically whether you have a hiatal hernia and whether it will be repaired. If you have esophagitis or Barrett's, expect a serious conversation about bypass rather than sleeve. After surgery, do not treat persistent heartburn as normal. Reflux that needs daily medication long term deserves investigation. None of this is a reason to avoid surgery. It is a reason to have the right one.

Your surgeon told you no ibuprofen, probably more than once, possibly with unusual firmness. This is why. It is also the part of post-operative instructions that gets quietly abandoned first, usually around the time a knee starts hurting or a dentist hands over a prescription without asking what operation you had. What a marginal ulcer isAfter a Roux-en-Y gastric bypass, the small gastric pouch is connected directly to the jejunum. That connection is called the gastrojejunal anastomosis, and the ulcer that forms just past it, on the jejunal side, is called a marginal ulcer. The jejunum is not built for acid. The stomach lining has a thick mucus layer, bicarbonate secretion, and a blood supply designed for the job. Jejunal mucosa has none of that. It normally sits downstream of the duodenum, where pancreatic bicarbonate has already neutralized whatever came out of the stomach. After a bypass, acid from the pouch hits it directly, and pepsin gets activated locally by that acidity. Add anything that impairs mucosal defense or blood supply, and you get an ulcer. Sleeve gastrectomy does not create this anatomy, so marginal ulcers are a bypass problem. Sleeve patients can still get ulcers, but the mechanism and location differ. How commonReported incidence after gastric bypass has a mean of about 4.6 percent, with individual studies ranging from 2.3 percent to 18.6 percent depending on whether they included asymptomatic patients and how long they followed people. An ASMBS literature review published in 2024 collects rates running from 0.9 percent at one year of follow-up to 11.4 percent at eight years. Most ulcers develop 6 to 12 months after surgery, but the reported range runs from 14 days to 20 years. There is no point past which you are safe, which is why the NSAID rule is permanent rather than temporary. The risk factors, ranked by how much control you haveNSAIDs. Associated with roughly a 3.1-fold increase in risk. Higher doses and chronic use matter more than an occasional low dose, but the safest position after a bypass is none. This includes ibuprofen, naproxen, diclofenac, ketorolac, meloxicam, indomethacin, aspirin above a cardiac-protective dose, and the many combination cold and headache products that contain one of them without saying so on the front of the box.Smoking. Smokers have a 56 percent higher hazard of developing a marginal ulcer, and 17.8 percent of smokers develop one within eight years. One review puts the risk increase as high as 4.6-fold. Even light smoking, under 10 cigarettes a day, raises risk. This includes nicotine in other forms; ask your surgeon specifically about vaping and nicotine pouches, because programs differ.Immunosuppression, including chronic steroids, associated with about a 4.6-fold increase.Poorly controlled diabetes. Each unit of HbA1c above 6.0 percent has been associated with a 23 percent increase in risk.Helicobacter pylori. The evidence is genuinely conflicting. Meta-analyses have found up to a tenfold increase in risk with H. pylori infection, while smaller controlled studies found no association and some found the opposite. The 2024 ASMBS review concluded that no strong recommendation can be made about testing for H. pylori specifically to prevent marginal ulcer. Many programs test and treat before surgery anyway, for other good reasons.A larger gastric pouch, because more parietal cell mass means more acid. In one case-control study, each 5 cubic centimeter increase in pouch volume carried about 2.4 times the odds of an ulcer. This is a surgical variable, not a patient one.How it feelsThe typical presentation is burning or gnawing pain high in the abdomen or behind the breastbone, often worse when the pouch is empty, sometimes relieved briefly by eating and then worse afterward. Nausea and a new intolerance of foods you were previously handling are common. Some people describe it as their restriction suddenly getting much tighter. Some marginal ulcers are silent until they bleed or perforate. Signs that an ulcer has bled include black tarry stools, vomiting material that looks like coffee grounds, lightheadedness, or a new anemia found on routine labs. Perforation causes sudden severe pain and a rigid abdomen. Both are emergencies. Diagnosis and treatmentUpper endoscopy is the gold standard, and it is the only reliable way to make the diagnosis. Routine endoscopy in patients without symptoms is not recommended, because asymptomatic ulcers are uncommon enough that screening does not pay off. Endoscopy is for people with symptoms. Treatment is acid suppression with a proton pump inhibitor, often combined with sucralfate, which coats the ulcer bed. Open-capsule PPI dosing, where the capsule is opened and the granules taken directly, is used because the small pouch and fast transit may not give an intact capsule time to dissolve where it should. In one series, patients treated with open-capsule PPIs had a median healing time of about three months. Smoking cessation and stopping the offending drug are part of the treatment, not optional additions to it. Most marginal ulcers heal medically. Surgery, in the form of revision of the anastomosis, is reported in 3.9 percent to 33 percent of cases across series, reserved for ulcers that will not heal, that keep coming back, that bleed uncontrollably, or that perforate. ProphylaxisProton pump inhibitors given routinely after bypass reduce the odds of marginal ulcer by 50 to 70 percent, and in one comparison dropped incidence from 7.3 percent to 1.2 percent. The 2024 ASMBS review recommends at least three months of PPI prophylaxis after gastric bypass. Longer courses are recommended for patients who smoke, who must take NSAIDs, who are on immunosuppression, or who have had an ulcer before. If you were sent home on a PPI, take it for the full course. Stopping it at week six because you feel fine is a common and avoidable mistake. The medication rules you were given, and the reasons behind themNothing else on this site covers post-operative medication management, so here it is in one place. These are general principles. Every specific decision about your own prescriptions belongs to your surgeon and your pharmacist together. FormulationBariatric anatomy changes drug absorption in several ways at once: a much smaller stomach means less room and less time for a tablet to disintegrate, gastric pH rises so acid-soluble drugs dissolve poorly, the available intestinal surface area is reduced after a bypass, and everything moves through faster. Extended-release, modified-release, enteric-coated and film-coated formulations should be avoided where possible. They are engineered to release drug slowly over a defined transit time. When transit is faster and the absorptive surface is shorter, a slow-release tablet can pass through without delivering its full dose. Immediate-release formulations are preferred.Liquid, dispersible or crushed forms are typically used for the first several weeks. Guidance from NHS Specialist Pharmacy Service suggests patients can usually return to solid dosage forms after roughly 6 to 8 weeks on a normal diet. Note that cutting or crushing a tablet may make its use off-label, so this is a question for your pharmacist rather than a decision to make at the kitchen counter.Choose low-sugar liquid preparations, since sugary syrups can provoke dumping.Avoid effervescent formulations, because the carbonation is poorly tolerated after surgery.MonitoringDo not assume a change is needed based on any one of these effects in isolation. What is called for is frequent monitoring for reduced effect or new side effects, particularly for drugs with a narrow therapeutic index. That means antiepileptics, thyroid hormone, lithium, warfarin, immunosuppressants, and psychiatric medications where a small change in level matters. Weight-based doses, levothyroxine being the standard example, need adjusting as your weight falls. Interactions with your supplementsCalcium impairs iron absorption, so iron and calcium supplements should be taken at separate times of day. Taking iron with 500 to 1000 mg of vitamin C, or with meat, improves absorption. If oral iron cannot keep up, intravenous iron is an option. Pain control without NSAIDsThis is the question everyone actually has. Acetaminophen is the usual first line. Topical agents, physical therapy, and non-drug approaches carry more weight than they did before your operation because the easy option is off the table. If you need something stronger, that is a conversation with your prescriber, who should know you have had a bypass. Tell every new clinician, every dentist, and every urgent care doctor. They will not think to ask.

Medicare and Medicaid get lumped together in conversation, and for bariatric surgery they could hardly be more different. Medicare has one national rule that applies in every state. Medicaid has fifty-some separate answers. If you are covered by either, the first thing to know is which of those two worlds you are in. What Medicare covers Medicare's coverage comes from National Coverage Determination 100.1, Bariatric Surgery for Treatment of Co-Morbid Conditions Related to Morbid Obesity. It has been in force since February 2006 and it names specific procedures. Nationally covered: Roux-en-Y gastric bypass, open and laparoscopic Biliopancreatic diversion with duodenal switch, also called gastric reduction duodenal switch, open and laparoscopic Laparoscopic adjustable gastric banding Sleeve gastrectomy sits in a different category. Since June 27, 2012, Medicare Administrative Contractors have had the authority to decide coverage of stand-alone laparoscopic sleeve gastrectomy within their own jurisdictions. In practice they generally do cover it. The local coverage determination for bariatric surgical management of morbid obesity covers laparoscopic sleeve gastrectomy as a stand-alone procedure. The practical consequence is that sleeve coverage is a regional decision, so confirm it with your own contractor rather than assuming. Nationally non-covered, meaning Medicare will not pay for them anywhere: Open adjustable gastric banding Open and laparoscopic vertical banded gastroplasty Open sleeve gastrectomy Intestinal bypass surgery Gastric balloon procedures The Medicare eligibility criteria You must meet all three: A body mass index of 35 or higher At least one comorbidity related to obesity. Type 2 diabetes has counted since February 2009. Previous unsuccessful medical treatment for obesity Note that Medicare's threshold is a BMI of 35 with a comorbidity, not 40. Note also that the third criterion is real and is where documentation problems arise. The local coverage determination expects failed medical treatment to be documented through participation in structured dietary programs overseen by a physician, a registered dietitian or another qualifying nutrition professional. It also expects documentation of comorbid conditions through physiologic testing or imaging, evidence of preoperative and postoperative evaluations, and a psychological evaluation for patients with a psychiatric history. The facility requirement, which no longer exists If you read older material, you will find that Medicare once required surgery to be performed at a facility certified under a specific bariatric accreditation program. That requirement was removed. As of September 24, 2013, facility certification is no longer required for coverage of covered bariatric procedures. That said, choosing an accredited center is still worth doing on quality grounds. The Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program, run by the American College of Surgeons, accredits centers after independent peer evaluation, and nearly 1,000 sites participate. You can search accredited centers through the ACS hospital finder. What you actually pay under Medicare Medicare.gov states that bariatric procedures are covered under Part B when you meet the conditions, and that your cost depends on your Part A deductible if you are admitted as an inpatient, your Part B deductible for physician and outpatient services, copayments after those deductibles, whether the surgery is done as an inpatient stay or in a hospital outpatient department or ambulatory surgical center, and whether your doctor accepts assignment. Medicare does not cover your transportation to a bariatric center. For 2026, the Part A inpatient hospital deductible is $1,736 per benefit period. The Part B annual deductible is $283, and the standard Part B monthly premium is $202.90. Coinsurance for inpatient days 61 through 90 is $434 per day. Original Medicare has no annual out-of-pocket maximum. That is why most people carry either a Medigap policy or a Medicare Advantage plan, and it is worth confirming what yours does before surgery rather than after. Medicare Advantage is not the same thing A Medicare Advantage plan must cover everything Original Medicare covers, so the national coverage determination still sets the floor. What differs is everything around it: Prior authorization. Original Medicare does not require prior authorization for bariatric surgery. Advantage plans routinely do, and the plan applies its own utilization criteria on top of the Medicare rules. Networks. Your surgeon and hospital have to be in the plan's network, or you pay much more, or nothing is covered at all. Cost sharing. Copayments and coinsurance are set by the plan, not by Medicare. Advantage plans do have an annual out-of-pocket maximum, which Original Medicare does not. Appeals. You appeal to the plan, on the plan's timeline, before you get to independent review. If you are in an Advantage plan, get the plan's own bariatric coverage policy in writing. Do not rely on the national coverage determination alone, and do not rely on what a hospital told a patient in a different plan. Medicaid: the honest answer is that it depends on your state Medicaid is a joint federal and state program, and states run their own. Federal law defines a set of mandatory benefits every state must cover, including inpatient and outpatient hospital services and physician services, and a set of optional benefits states may choose. Beyond that, Medicaid.gov states plainly that states establish and administer their own programs and determine the type, amount, duration and scope of services within broad federal guidelines. Bariatric surgery is not named in the federal mandatory list. What that means in practice: Some state Medicaid programs cover bariatric surgery with criteria that look much like commercial policies. Some cover it with tighter criteria, longer supervised weight loss requirements, or a narrower list of approved procedures. Some do not cover it. Coverage changes. A state that did not cover it three years ago may cover it now, and the reverse happens too. Anyone who tells you confidently what Medicaid covers without asking which state you live in is guessing. So is any national list you find online, because those lists go stale fast and the underlying rules move. How to get the real answer for your state Do these in order. Call your state Medicaid agency directly and ask whether bariatric surgery is a covered service, and if so, what the medical necessity criteria are. Ask for the coverage policy or provider manual section in writing. Use the same phrasing that works with commercial plans: ask whether it is covered when it is medically necessary, not simply whether it is covered. If you are in a Medicaid managed care plan, and most enrollees are, call the managed care plan too. The plan administers the benefit and applies its own prior authorization criteria within what the state allows. Call a bariatric program in your state and ask their insurance coordinator whether they take Medicaid and how often those cases get approved. Coordinators at high-volume centers know the current state of play better than any published document. Ask about the specific procedure. A state may cover sleeve gastrectomy and not duodenal switch, or the reverse. Ask about revisions separately. Coverage of a first operation tells you nothing about coverage of a second. Find your own state, in one click The Obesity Action Coalition keeps a directory of state agencies, and for each state it lists the Medicaid agency, the Department of Insurance and the state health department, with phone numbers and addresses. The Department of Insurance entry matters as much as the Medicaid one, because that is the office you escalate to when a commercial plan denies you and the internal appeal goes nowhere. One caveat before you use it. Some of these pages are old enough that the agency names have changed since they were written, and a few of the outbound links point at web addresses the states have since retired. Treat the phone numbers and the agency identity as the useful part, and search for the current website yourself if a link does not resolve. AlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirginiaWashingtonWashington DCWest VirginiaWisconsinWyoming A fair number of states do not call their program Medicaid at all, which is a common source of confusion when you are searching. California runs Medi-Cal, Tennessee runs TennCare, Kansas runs KanCare, Maine runs MaineCare, Connecticut runs HUSKY, Arizona runs AHCCCS, Hawaii runs Med-QUEST, Oregon runs the Oregon Health Plan and Vermont runs Green Mountain Care. If a search for your state plus the word Medicaid returns nothing useful, search the program name instead. For the program itself rather than the contact details, the federal Medicaid site publishes a profile for every state and territory covering eligibility and enrollment. It will not tell you whether bariatric surgery is covered, because that sits in state policy manuals rather than in the federal profile, but it is the right place to confirm what your state actually runs and who runs it. If you are covered by both If you are dually eligible for Medicare and Medicaid, Medicare pays first and Medicaid may cover some of what Medicare leaves. That combination can be favorable, but it also means two sets of rules and two sets of prior authorization. Ask the bariatric program's coordinator to walk you through the order of operations before you start, because getting the sequence wrong creates denials that are tedious to unwind. The part worth being blunt about Public coverage for bariatric surgery is real and it works, and it is also the slowest lane in this system. Documentation requirements tend to be stricter, approval timelines longer, and the list of participating centers shorter. None of that means you will not get there. It means you should start earlier than a commercially insured person would, keep every piece of paper, and be prepared to ask the same question three times before you get a consistent answer.

The adjustable gastric band, sold in the United States mainly as the LAP-BAND System, was one of the most widely performed weight loss operations in the country in the late 2000s and early 2010s. It is almost never placed today. BariatricPal began as a band community, and many of our members are current or former band patients. If you still have a band, it is still an implant in your body, and it still needs a care team. This page covers what a gastric band is, what the device labeling and long-term research actually say, why practice moved away from the band, what daily life with one involves, and which questions belong with your surgical team. It does not tell you whether to keep your band, empty it, or have it removed. That decision belongs to you and the clinicians who know your history. What a Gastric Band Is and How It Works A gastric band is a silicone ring placed around the upper part of the stomach. The FDA summary of safety and effectiveness data for the LAP-BAND System describes it as forming "a small gastric pouch and stoma": a small pouch above the band and a narrow outlet through which food passes into the rest of the stomach. The band is connected by thin tubing to an access port stitched under the skin of the abdomen. A clinician adds or removes sterile saline through that port to make the band tighter or looser, which is what people mean by a fill or an unfill. The FDA-approved labeling calls the device "a long-term implant" and notes that "explant (removal) and replacement surgery may be indicated at any time." The band works mainly by limiting how much food fits in the pouch at once and how fast it moves past the band. It does not reroute or remove any part of the digestive tract. The 2019 clinical practice guidelines from AACE, TOS, ASMBS, OMA and ASA list "no anatomic alteration" and "removable" as favorable aspects of the band, and list metabolic effects as a favorable aspect of sleeve gastrectomy and gastric bypass but not of the band. Why the Band Fell Out of Favor This is the question members ask most often, and it deserves dates and numbers rather than rumor. Approval and labeling history The FDA approved the LAP-BAND Adjustable Gastric Banding System under premarket approval P000008. The summary of safety and effectiveness data records the "Date of Notice of Approval to the Applicant" as June 5, 2001, applicant BioEnterics Corporation. The original indication covered "severely obese patients with a Body Mass Index (BMI) of at least 40 or a BMI of at least 35 with one or more severe comorbid conditions." The indication was later widened. The FDA-approved directions for use for the LAP-BAND AP System state that the device "is indicated for weight reduction for patients with obesity" at a BMI of at least 40, or at least 30 with one or more obesity related comorbid conditions. The device did not lose its approval and was not withdrawn. What changed was how often surgeons chose it. How sharply use dropped The American Society for Metabolic and Bariatric Surgery publishes an annual estimate of bariatric procedure numbers in the United States. In its 2011 through 2023 table, band procedures fall from 55,932 in 2011 to 773 in 2023, while total procedures rose from about 158,000 to about 270,089. The band went from a large share of a smaller field to a rounding error in a much larger one. The 2022 joint ASMBS and IFSO statement says the same thing plainly: "the dominant procedures are sleeve gastrectomy and RYGB, together accounting for approximately 90% of all operations performed worldwide," and "the popularity of the AGB has diminished significantly over the past decade." What the long-term studies found Three findings drove that change. Each comes with real limits, and those limits matter when you read them about your own band. Weight loss averaged lower than with bypass. A 2019 systematic review and meta-analysis by O'Brien and colleagues pooled reports with 10 or more years of follow-up. Across 17 reports of band surgery the weighted mean was 45.9% excess weight loss, against 56.7% across 18 reports of gastric bypass. Averages across pooled studies say very little about any one person. Reoperation was common. A 2017 JAMA Surgery study of 25,042 Medicare beneficiaries banded between 2006 and 2013 found that, at an average of 4.5 years of follow-up, 18.5% had a device-related reoperation, averaging 3.8 procedures each. Rates varied roughly threefold between regions, so no single national number describes every program. Late device complications were documented. A 2011 Archives of Surgery study followed patients 12 or more years after banding at one Belgian center. Among the 82 of 151 patients who could be evaluated, 39% had a major complication and 28% had band erosion. That is a small early-era cohort with 54.3% follow-up, and bands and techniques changed afterward, so read it as what can happen over time rather than as your personal risk. The FDA-approved labeling itself reports that "data from a post-approval study showed an estimated explant rate of 6.5% per year over the first five years following implantation." None of this means the band never worked. O'Brien's single-centre cohort of 8,378 band patients, followed up to 20 years with a 54% follow-up rate and no surgical deaths, still showed durable weight loss in the small group that reached 20 years, and plenty of BariatricPal members have lived well with a band for a decade or more. It does mean that surgeons weighing a first operation today generally choose something else. Living With a Band Day to Day The habits band patients describe are consistent, for a mechanical reason: food has to pass a narrow outlet. Small bites, thoroughly chewed. Cutting food small and chewing well is the habit longtime band patients mention most. Slow pace. Putting utensils down between bites, and waiting until you have actually swallowed before preparing the next one, is the version of "eat slowly" people find practical to sustain. Satisfied is not the same as full. Members often describe learning to stop at "no longer hungry," because by the time a band patient feels full, food may already be backing up above the band. Restriction is not constant. Band patients report that how the band feels varies by time of day, hydration, illness, stress, and whether food is solid or soft. A permanent "sweet spot" does not match most people's experience, or a device whose fluid volume the labeling expects to be adjusted over time. Soft and liquid calories slip through. Foods that pass the band easily also tend to provide the least satiety, a recurring theme in member accounts of stalling with a tight band. Not everything is your band. A stomach bug is usually a stomach bug. Alertness is appropriate, but attributing every symptom to the band can delay the right diagnosis. These are practical observations from band patients in this community, not a clinical protocol. Your dietitian can tell you which apply to you. Stalls and regain Weight loss slowing or stopping is one of the most common reasons band patients come back to the forums, and one of the easiest things to misread. The FDA-approved labeling warns clinicians directly: "Insufficient weight loss may be a symptom of inadequate restriction (band too loose), or pouch or esophageal enlargement, and may be accompanied by other symptoms, such as heartburn, regurgitation or vomiting. If this is the case, inflation of the band would not be appropriate." The same symptom can point in opposite directions, and telling those apart takes imaging and an exam, not a guess. If your weight loss has stalled or reversed, the useful move is an appointment. Fills, Unfills, and Why They Belong to Your Clinician Adjustments are the defining feature of the band, and the part of band life most often described wrongly online. The FDA-approved labeling gives clinicians general guidelines: the initial postoperative adjustment "should occur at six weeks or more after placement," and the patient "should be reviewed regularly (every 4-6 weeks), depending on patient need." Fluid is removed, not added, "if there were symptoms of excessive restriction or obstruction, including excessive sense of fullness, heartburn, regurgitation and vomiting." Those are instructions to the clinician, and they describe an active adjustment phase after a new placement, which is not where most readers of this page are. If your band was placed years ago, ask your team what follow-up interval makes sense for you now rather than assuming a schedule. The labeling also names situations in which "elective deflation of the band is advisable": pregnancy, significant concurrent illness, general anaesthesia, remote travel, and travel to areas where food or water contamination is endemic. If any of those are on your horizon, that is a well-founded reason to call your surgeon's office in advance rather than after. One warning in the labeling is unambiguous: "Patient self-adjustment of superficially placed access ports has been reported. This can result in inappropriate band tightness, infection and other complications." Do not adjust your own port, and do not let anyone untrained on your device do it. Follow-Up, Labs, and Supplements The band does not bypass or remove any part of the digestive tract, so it is not a malabsorptive operation. Follow-up is still not optional, because eating less food means taking in fewer nutrients. The 2019 clinical practice guidelines set out procedure-specific baselines. For band patients the postprocedure checklist lists one multivitamin plus minerals tablet as the minimum requirement, elemental calcium as calcium citrate at 1,200 to 1,500 mg per day, and vitamin D at "at least 3,000 units/d, titrate to >30 ng/mL." The same table gives band follow-up visits at 1 month, then 1 to 2 months, then every 12 months once stable. Treat those as the start of a conversation, not a prescription. Doses depend on your labs, your other conditions, and your other medications, and only the clinician who can see your bloodwork should set them. Ask your program which supplements and which lab panel they want for you, and how often. Problems That Belong With Your Surgical Team The device labeling lists the recognized adverse events of gastric banding. Knowing their names helps you describe symptoms accurately. It is not a basis for diagnosing yourself, and none of these can be managed at home. Band slippage and pouch dilatation. The labeling states that reflux, nausea or vomiting with early or minor slippage "may be successfully resolved by band deflation in some cases," and that "more serious slippages may require surgery to reposition and/or remove the band." Erosion. The labeling notes a risk of the band eroding into stomach tissue, lists possible symptoms as "reduced weight loss, weight gain, Access Port infection, or abdominal pain," and states that "reoperation to remove the device is required." Esophageal dilatation. Reported as a consequence of incorrect placement, over-restriction or stoma obstruction. "Deflation of the band is recommended if esophageal dilatation develops." Stoma obstruction. Reported as both an early and a late complication, attributed in the labeling to causes including swelling, food, band slippage, and choice or chewing of food. Port and device problems. Infection "can occur in the immediate post-operative period or years after insertion of the device," and unplanned deflation can happen through leakage from the band, the port, or the tubing. The 2019 guidelines give clinicians an explicit pathway here. Recommendation 78 states that "persistent vomiting, regurgitation, and upper-gastrointestinal (GI) obstruction after laparoscopic adjustable gastric banding (LAGB) should be treated with immediate removal of fluid from the adjustable band," and that "persistent symptoms of gastroesophageal reflux, regurgitation, chronic cough, or recurrent aspiration pneumonia in a patient after LAGB raise concern for band slippage, esophageal dilation, and, in some cases, erosion," and should prompt endoscopy or fluoroscopy and "immediate referral to a bariatric surgeon." Two things follow. A chronic cough or ongoing reflux is a reason to be seen, not to wait out. And if you are told to come in for an unfill, that matches published guidance and is not your team giving up on you. When to Seek Emergency Care Go to the emergency department, or call emergency services, if you have any of the following: Severe abdominal pain, especially if it is worsening Inability to swallow your own saliva Vomiting that will not stop, or inability to keep down clear liquids Fever and chills Shortness of breath or chest pain Vomiting blood, or black tarry stools Tell the emergency team you have an adjustable gastric band and roughly when it was placed. Clinicians who rarely see band patients may not think of the device first, and they may need to contact a bariatric surgeon about whether fluid should be removed from your band. If You Are Thinking About Removal or Conversion Some band patients keep their band for decades. Others have it removed, alone or with a conversion to another procedure. This page does not recommend any of those paths. What the data show is that band conversions are routine bariatric practice rather than an unusual event. A 2022 analysis of the 2020 MBSAQIP database found that of 168,548 bariatric operations, 20,387 (12.1%) were revisional, and adjustable gastric banding was the index operation in 45.9% of the conversions. The most frequent were band to sleeve gastrectomy (27%) and band to Roux-en-Y gastric bypass (16.2%), most often for weight loss failure. Across all conversion types studied, overall morbidity ranged from 5.3% to 20.8% and mortality from 0% to 0.8%. These are real operations with real risk that depends on which conversion and which patient. Our revision pages cover what those consultations involve. Questions Worth Bringing to Your Appointment Given how long my band has been in place, what follow-up interval do you want for me? What imaging, if any, do you want to check my band position and the size of my pouch and esophagus? What supplements and lab panel do you want for me, and how often? My reflux, cough, regurgitation, or trouble swallowing has gone on a while. What should we rule out? I have surgery, a pregnancy, or long-distance travel coming up. Should anything change beforehand? If I had the band removed, what would you recommend about conversion, and what are the risks either way? Who do I call after hours, and what should I tell an emergency department that does not know my history? What This Page Is Not This is educational material. It is not medical advice, not a diagnosis, and it does not recommend starting, stopping, or changing any treatment, fill, unfill, or operation. Symptoms that sound alike can have very different causes, and only a clinician who can examine and image you can tell them apart. Members' experiences described here are one person's experience, not evidence about what will happen to you. Related Reading Types of Revision Surgeries and What They Involve What removal and conversion operations involve. When to Consider a Revision Surgery How these conversations start. The Bariatric Procedures Done Today, Compared Where the band sits next to current operations. GERD, Reflux, and How It Changes Your Procedure Choice Useful if reflux is your main symptom. Types of Bariatric Procedures A plain overview of the options. References U.S. Food and Drug Administration. Summary of Safety and Effectiveness Data: LAP-BAND Adjustable Gastric Banding (LAGB) System, PMA P000008. Date of Notice of Approval to the Applicant, June 5, 2001. Allergan. LAP-BAND AP System Directions for Use. FDA-approved labeling under PMA P000008, supplement S017. American Society for Metabolic and Bariatric Surgery. Estimate of Bariatric Surgery Numbers, 2011-2023. Eisenberg D, Shikora SA, Aarts E, et al. (2022). 2022 ASMBS and IFSO Indications for Metabolic and Bariatric Surgery. Surgery for Obesity and Related Diseases, 18(12), 1345-1356. Mechanick JI, Apovian C, Brethauer S, et al. (2019). Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures, 2019 Update. Endocrine Practice, 25(12), 1346-1359. O'Brien PE, Hindle A, Brennan L, et al. (2019). Long-Term Outcomes After Bariatric Surgery: a Systematic Review and Meta-analysis of Weight Loss at 10 or More Years. Obesity Surgery, 29(1), 3-14. DOI: 10.1007/s11695-018-3525-0 Ibrahim AM, Thumma JR, Dimick JB (2017). Reoperation and Medicare Expenditures After Laparoscopic Gastric Band Surgery. JAMA Surgery, 152(9), 835-842. DOI: 10.1001/jamasurg.2017.1093 Himpens J, Cadiere GB, Bazi M, et al. (2011). Long-term Outcomes of Laparoscopic Adjustable Gastric Banding. Archives of Surgery, 146(7), 802-807. DOI: 10.1001/archsurg.2011.45 Vanetta C, Dreifuss NH, Schlottmann F, et al. (2022). Bariatric Surgery Conversions in MBSAQIP Centers: Current Indications and Outcomes. Obesity Surgery, 32(10), 3248-3256. DOI: 10.1007/s11695-022-06229-z Questions about The Lap Band: What Happened, and What To Do If You Still Have OneWas the band recalled?The band has not been withdrawn from the market. The FDA approved it in 2001 under PMA P000008 and its approved labeling remains in force. What changed is how rarely surgeons choose it for a first operation. Do I have to have my band removed?No page can answer that. Some people keep a band for years without a problem, others have it removed or converted. That call depends on your symptoms, imaging, and history, so it belongs with a bariatric surgeon who can examine you. Can I adjust my own port?No. The FDA-approved labeling reports that patient self-adjustment of access ports has occurred and can cause inappropriate band tightness, infection and other complications. About the authorAlex Brecher founded BariatricPal, an online community for people considering or living with bariatric surgery.